NUVB
Nuvation Bio Inc. (NYSE)
Healthcare — Biotechnology
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Strong Buy
1.4 / 5
9 analysts
$6.55
+$0.12 (+1.87%)
Target:
$12.33
(88.3%)
Sign in to add NUVB to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $1.89B |
| P/E Ratio (TTM) | - |
| Forward P/E | -90.33 |
| EPS (TTM) | $-0.43 |
| Dividend Yield | - |
| Profit Margin | -102.06% |
| Revenue Growth | 2598.70% |
| ROE | -39.51% |
| Debt/Equity | 67.90 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $12.33 |
| Analysts | 9 |
| Indexes | NYSE |
Technical Indicators
| RSI (14) | 63.5 |
| Beta | 1.56 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.75 |
| 52-Week Low | $2.01 |
| 50-Day Avg | $4.95 |
| 200-Day Avg | $5.42 |
| Avg Volume | $6.32M |
| Volume | $6.95M |
Performance Analysis
BULLISHNUVB shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 59% of its 52-week range.
+
RSI at 63.5 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Strong revenue growth of 2598.7% year-over-year.
-
Operating at a loss with -102.1% margin.
+
Wall Street consensus is "Strong Buy" from 9 analysts.
+
Average analyst target of $12.33 implies 88.3% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report